Results 201 to 210 of about 3,492,883 (216)

ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy

Archives of pharmacal research, 2021
Seong-Jun Park, S. Joo, Na-Gyeong Lee, Won-Jun Jang, J. Seo, C. Jeong   +5 more
semanticscholar   +1 more source

Erlotinib in Combination with Capecitabine (5'dFUR) in Resistant Pancreatic Cancer Cell Lines

Journal of Chemotherapy, 2010
The combination of capecitabine and the tyrosine kinase inhibitor erlotinib has recently been tested in patients with gemcitabine-refractory pancreatic tumors, with limited success. To understand this lack of efficacy, we studied the molecular effects of these agents in Capan-1 and Capan-2 human pancreatic resistant cancer cells. Erlotinib up-regulated
M, Chefrour, J-L, Fischel, P, Formento, S, Giacometti, R-M, Ferri-Dessens, H, Marouani, M, Francoual, N, Renée, C, Mercier, G, Milano, J, Ciccolini   +10 more
openaire   +2 more sources

Lung Adenocarcinoma With Acquired Resistance to Erlotinib: Does Retreatment With Erlotinib Work

Chest, 2012
Tushar Chopra, Grace Dy, Nazneen Tata
openaire   +1 more source

Inhibiting FGFR by toadflax reverses erlotinib resistance in nonsmall cell lung cancer

Anti-Cancer Drugs
This study aims to demonstrate the effect of toadflax (bufalin) on erlotinib resistance in nonsmall cell lung cancer (NSCLC) by inhibiting the fibroblast growth factor receptor (FGFR). The microfluidic mobility transferase and caliper mobility-shift assays were employed to detect the FGFR inhibition by bufalin and the binding reversibility.
Bateer, Han, Ying, Ma, Shuguang, Bao, Hui, Gao, Yanqing, Gao, Qiang, Guo, Ao, Li, Meitao, Li, Rong, Yu, Hongwei, Wang   +9 more
openaire   +2 more sources

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

Cancers, 2022
Bei Qing, Yiqun Jiang
exaly  

[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].

Revue des maladies respiratoires, 2014
The characterization of genetic abnormalities in non-small cell lung cancer (NSCLC) constitutes a theranostic revolution which is leading to rapid progress in the personalized management of this condition.We present the case of a patient with NSCLC harboring an activating mutation of the Epidermal Growth Factor Receptor (EGFR).
C, Rieux, M, Boisdron-Celle, A, Morel, L, Fey, T, Urban, J, Hureaux   +5 more
openaire   +1 more source

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients

Cancers, 2019
Junji Uchino, Tadaaki Yamada
exaly  

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

Journal of Thoracic Oncology, 2011
Kenichi Suda, Yoshihiko Maehara, Yasushi Yatabe   +2 more
exaly  

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed

Journal of Thoracic Oncology, 2013
f214G808, Shigeki Mitsuoka, Tatsuo Kimura   +2 more
exaly  

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

Head and Neck, 2014
Jeong Hun Hah, Curtis R Pickering, Daisuke Sano   +2 more
exaly